Last checked at 3 May 2023 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx to Present Additional Preclinical Efficacy of RXC007 and DDR1/2 Inhibitors in Cancer-Associated-Fibrosis Models at The Resistant Tumour Microenvironment, Keystone Symposia
Alderley Park, UK, 3 May 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease announces additional preclinical data from the company's fibrosis portfolio including data on lead asset RXC007, and Discodin Domain Receptor (DDR) 1/2 inhibitors will be presented both orally and in a poster, at The Resistant Tumour Microenvironment, Keystone Symposia (7-10 May 2022, Vancouver, BC, Canada).
During the session on Wednesday 10th May 0830-1130am PDT: 'Friend or Foe: Should we Target Cancer Associated Fibroblasts and the ECM?' Redx Senior Scientist, Dr. Daniel Wilcock will discuss if targeting tumor fibrosis with small molecule inhibitors of Rho Associated Coiled Coil Containing Protein Kinase 2 (ROCK2) or DDR1/2 improves therapy response in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC). Data presented will be from the Company's lead fibrosis asset, RXC007 as well as the DDR discovery programme, which further complements the data set presented last year at the Extracellular Matrix Pharmacology Congress by collaboration partner, the Garvan Institute of Medical Research.
In addition to Dr Wilcock's presentation, Redx will present a poster which details the potential of RXC007 in an aggressive patient derived xenograft model of PDAC in combination with standard of care (SoC) chemotherapy, and DDR1/2 inhibition in a TNBC model in combination with anti-PD-1.
RXC007, the Company's lead asset, is a highly potent, selective and orally-active ROCK2 inhibitor targeting multiple diseases associated with fibrosis, initially being developed for interstitial lung diseases. A Phase 2a study assessing RXC007 as a potential treatment for patients with idiopathic pulmonary fibrosis (IPF) is expected to report topline data in Q1 2024.
Details of the presentation are as follows:
Title: | Targeting tumor fibrosis with small molecule inhibitors of ROCK2 or DDR1/2 improves therapy response in preclinical models of PDAC &TNBC
|
|
|
| |
Session: | Friend or Foe: Should we Target Cancer Associated Fibroblasts and the ECM? |
|
| ||
Day/Date: | Wednesday 10th May, 2023 | |
Time: | 08:30-11:30 am PDT | |
A copy of the poster will be made available on the Company's website following the presentation at: https://www.redxpharma.com/scientific-publications/
For further information, please contact: |
| |||
| ||||
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications ir@redxpharma.com
Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 | |||
US Office Peter Collum, Chief Financial Officer | ||||
| ||||
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 | |||
Matt Davis/ Adam Dawes | ||||
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 | |||
Claes Spång/ Satheesh Nadarajah/ David Wilson | ||||
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 | |||
Rupert Dearden/ Freddy Crossley/ Emma Earl | ||||
FTI Consulting | T: +44 (0)203 727 1000 | |||
Simon Conway/ Ciara Martin | ||||
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease being evaluated in a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in Q1 2024. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report Phase 2 data in combination with anti-PD-1 by end 2023. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA application in H2 2023.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/